NDUFS2 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NDUFS2 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NDUFS2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NDUFS2</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=NDUFS2" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">28 edges</a></td>
</tr>
</table>
NDUFS2 is a core catalytic subunit of mitochondrial Complex I and is essential for coupling NADH oxidation to ubiquinone reduction and proton motive force generation. In the brain, this function is central to neuronal ATP homeostasis, synaptic transmission, and resistance to oxidative stress. Pathogenic [NDUFS2](/genes/ndufs2) variants can produce severe mitochondrial encephalopathies, and partial Complex I impairment is mechanistically linked to broader neurodegenerative phenotypes.
Molecular Role In Complex I
...NDUFS2 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NDUFS2 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NDUFS2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NDUFS2</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=NDUFS2" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">28 edges</a></td>
</tr>
</table>
NDUFS2 is a core catalytic subunit of mitochondrial Complex I and is essential for coupling NADH oxidation to ubiquinone reduction and proton motive force generation. In the brain, this function is central to neuronal ATP homeostasis, synaptic transmission, and resistance to oxidative stress. Pathogenic [NDUFS2](/genes/ndufs2) variants can produce severe mitochondrial encephalopathies, and partial Complex I impairment is mechanistically linked to broader neurodegenerative phenotypes.
Molecular Role In Complex I
Complex I is a multi-subunit megacomplex with catalytic modules in the matrix arm and proton-pumping modules in the membrane arm. NDUFS2 sits in the catalytic core near the quinone reduction site and participates in gating electron transfer into ubiquinone chemistry.[@kampjut2020][@fiedorczuk2016] Because this region is tightly coupled to conformational transitions that drive proton pumping, NDUFS2 perturbation can reduce both electron flux and energetic efficiency.[@kampjut2020][@hirst2013]
In practical terms, NDUFS2 dysfunction can manifest as:
- Lower ATP production under high neuronal workload
- Increased electron leak and [ROS](/entities/reactive-oxygen-species) generation
- Greater susceptibility to mitochondrial depolarization during stress
These effects are especially relevant in long-projection [neurons](/entities/neurons) and autonomous pacemaker populations with high oxidative phosphorylation dependence.[@schapira2008][@johri2012]
Neurodegeneration-Relevant Mechanisms
NDUFS2-related bioenergetic stress intersects with canonical disease pathways:
Mitochondrial ROS and redox imbalance contributing to lipid/protein oxidation and mtDNA injury[@schapira2008][@johri2012]
Proteostasis burden from ATP-dependent chaperone and proteasome insufficiency, which can intensify aggregate-prone states[@wang2010]
Mitophagy stress requiring [PINK1](/genes/pink1)/[PRKN](/genes/prkn)-mediated quality control to prevent toxic mitochondrial accumulation[@pickrell2015]
Inflammatory amplification through mitochondrial danger-signaling and glial activation loops[@johri2012][@wilkins2017]This cross-talk helps explain why Complex I deficits are repeatedly observed in [Parkinson's disease](/diseases/parkinsons-disease) and are increasingly modeled in Alzheimer's- and tauopathy-relevant systems.[@schapira2008][@lake2016][@johri2012]
Human Disease Associations
Biallelic NDUFS2 variants are established causes of mitochondrial disease, including infantile-onset Leigh syndrome and related encephalomyopathic phenotypes.[@lake2016][@distelmaier2009] Clinical findings often include developmental delay/regression, movement abnormalities, and characteristic neuroimaging lesions in high-metabolic CNS regions.[@lake2016][@distelmaier2009]
Although these inherited syndromes are rare, they provide high-confidence causal evidence that persistent Complex I dysfunction alone can be sufficient to produce progressive neurodegeneration.[@lake2016] This makes NDUFS2 a valuable anchor for mechanistic stratification in mitochondrial-targeted trials.
Biomarker And Trial-Relevant Readouts
For NDUFS2-centered studies, common mechanistic readouts include:
- Complex I activity assays in fibroblasts/muscle and high-resolution respirometry[@distelmaier2009]
- Lactate and metabolic stress signatures in symptomatic periods[@lake2016]
- MRI patterns consistent with mitochondrial network vulnerability[@lake2016][@distelmaier2009]
- Exploratory CSF/plasma stress biomarkers (oxidative and inflammatory panels) in adult neurodegeneration contexts[@johri2012][@wilkins2017]
A key translational challenge is separating primary target engagement from downstream compensation. Multi-domain biomarker panels are generally more informative than single markers.[@schapira2008][@johri2012]
Therapeutic Considerations
No approved intervention directly corrects NDUFS2 loss-of-function. Current care is supportive in inherited mitochondrial disease and symptom-oriented in adult neurodegeneration. Mechanistically plausible adjunct strategies include:
- Respiratory chain support with [coenzyme Q10](/therapeutics/coenzyme-q10-neurodegeneration) analogs[@beal2004]
- Metabolic cofactor support via [NAD+ precursors](/therapeutics/nad-precursors-neurodegeneration)[@lautrup2019]
- Resilience-focused combinations from [mitochondrial neuroprotection](/therapeutics/mitochondrial-neuroprotection), including exercise and anti-inflammatory coupling[@schapira2008][@beal2004]
Future directions include vectorized or RNA-based correction for severe monogenic disease, but CNS delivery, dosage control, and long-term safety are unresolved.
Research Priorities
Priority gaps for NDUFS2 in translational neurodegeneration research:
- Define threshold levels of NDUFS2 impairment that predict irreversible neuronal decline.
- Distinguish NDUFS2-specific biology from general Complex I failure in biomarker development.
- Build trial enrichment frameworks using combined genetic, metabolic, and imaging signatures.
See Also
- [NDUFS2](/genes/ndufs2)
- [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Coenzyme Q10 and Neurodegeneration](/therapeutics/coenzyme-q10-neurodegeneration)
- [Mitochondrial Neuroprotection](/therapeutics/mitochondrial-neuroprotection)
External Links
- [UniProt: ndufs2](https://www.uniprot.org/)
- [PubMed: ndufs2](https://pubmed.ncbi.nlm.nih.gov/?term=ndufs2+neurodegeneration)
References
[Kampjut D, Sazanov LA, The coupling mechanism of mammalian respiratory complex I (2020)](https://doi.org/10.1126/science.abc4209)
[Hirst J, Mitochondrial complex I (2013)](https://doi.org/10.1146/annurev-biochem-070511-103700)
[Schapira AHV, Mitochondrial pathology in Parkinson's disease (2008)](https://doi.org/10.1016/S1474-4422(08)
[Lake NJ, Compton AG, Rahman S, Thorburn DR, Leigh syndrome: one disorder, more than 75 monogenic causes (2016)](https://doi.org/10.1016/S1474-4422(15)
[Fiedorczuk K, Letts JA, Degliesposti G, Kaszuba K, Skehel M, Sazanov LA, Atomic structure of the entire mammalian mitochondrial complex I (2016)](https://doi.org/10.1038/nature19794)
[Johri A, Beal MF, Mitochondrial dysfunction in neurodegenerative diseases (2012)](https://doi.org/10.1177/1759091411423216)
[Wang X, Michaelis EK, Selective neuronal vulnerability to oxidative stress in the brain (2010)](https://doi.org/10.1016/j.freeradbiomed.2010.07.001)
[Pickrell AM, Youle RJ, The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease (2015)](https://doi.org/10.1016/j.neuron.2015.06.007)
[Wilkins HM, Swerdlow RH, Mitochondrial links between brain aging and Alzheimer's disease (2017)](https://doi.org/10.1038/s41582-016-0008)
[Distelmaier F, Koopman WJH, van den Heuvel LP, Rodenburg RJ, Mayatepek E, Willems PH, Smeitink JAM, Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19818403/)
[Beal MF, Coenzyme Q10 administration and its potential for neurodegenerative disorders (2004)](https://doi.org/10.1002/mus.20144)
[Lautrup S, Sinclair DA, Mattson MP, Fang EF, NAD+ in brain aging and neurodegenerative disorders (2019)](https://doi.org/10.1016/j.cmet.2019.06.001)